Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Samuel Isaly’s Orbimed Advisors Sells Some Intercept Pharmaceuticals Stock at $62.50/Share

Orbimed Advisors, Intercept Pharmaceuticals: Samuel Isaly and his hedge fund, Orbimed Advisors, is focused on healthcare stocks. They recently reported selling a piece of their stake in Intercept Pharmaceuticals Inc (NASDAQ:ICPT). Orbimed unloaded 40,088 shares of the company with a selling price of $62.50 apiece, slightly above the current stock price. Following the sale, Orbimed still owns around 1.7 million shares of Intercept.

Intercept Pharmaceuticals Inc (NASDAQ:ICPT)

Disclosure: none